Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Triple-negative breast cancer, or TNBC, is a rare and especially aggressive form of breast cancer that grows and spreads ...

Publicly traded Peninsula drugmaker Gilead Sciences Inc. is trimming its Bay Area workforce after it announced it would do ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc.

Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...